Sidewinder Therapeutics
Advancing precision bispecific antibody-drug conjugates to treat cancer
First Investment: 2016
In Newfoundland and Labrador, the founder effect means there’s less genetic variability, making it easier to use population multi-omics to find true signals of disease — gene variants with low frequency but high impact. Sequence Bio works with leading pharma and biotech companies to discover better drug targets, build custom cohorts of volunteers for clinical trials, and shorten R&D timelines.
